Digital Therapies

Apple Watch prescription sleep app from NightWare earns FDA approval | Business Insider | 11/11/2020

Digital therapeutic companies are rolling out mental health tools rapidly thanks to a friendlier stance from the FDA‚Äîthey're even using the Apple Watch to manage PTSD. And agencies like the CMS will start covering digital therapies for their enrollees, giving developers access to large, untapped user bases. publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. For a limited …

Orexo Interim Report Q3 2020 - GuruFocus.com | 11/4/2020

… launch US Pharma segment (ZUBSOLV¬Æ US) net revenues of SEK 143.8 m (182.7), EBIT of SEK 72.4 m (90.9) DTx segment EBIT of SEK -62.5 m (-), including US launch of the scientifically proven digital therapies deprexis¬Æ and vorvida¬Æ Cash flow from operating activities of SEK -12.9 m (135.7), a cash balance of SEK 593.3 m (812.9) Orexo US received subpoenas to provide US authorities with certain information …

Orexo Interim Report Q3 2020 | BioSpace | 11/4/2020

… launch US Pharma segment (ZUBSOLV¬Æ US) net revenues of SEK 143.8 m (182.7), EBIT of SEK 72.4 m (90.9) DTx segment EBIT of SEK -62.5 m (-), including US launch of the scientifically proven digital therapies deprexis¬Æ and vorvida¬Æ Cash flow from operating activities of SEK -12.9 m (135.7), a cash balance of SEK 593.3 m (812.9) Orexo US received subpoenas to provide US authorities with certain information …

Asabys Partners leads a round of $20 million in Sidekick | 10/29/2020

Asabys has recently led a successful round of financing in Sidekick, a company specialized in digital therapies . This round will allow the company to advance and consolidate growth in Europe and expand its operations to the U.S. Sidekick‚Äôs fundraising efforts have been supported by EIT Digital Accelerator. The company was chosen by EIT Digital as one of the top ten fastest growing high-tech companies in Europe. 0 Suzanne …

Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders | PR Newswire | 10/16/2020

UPPSALA, Sweden and NEW YORK Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies , and Lyfebulb, a patient empowerment platform, announced that Rohan Dixit of Lief Therapeutics was chosen as the winner of the Lyfebulb and Orexo Innovation Challenge: Solutions for Substance Use Disorders. Lief Therapeutics has developed a wearable device that helps reduce stress and anxiety in real time using heart rate variability biofeedback training. The …

New Ventures Funds Rebrands as Scientia Ventures | PR Newswire | 10/2/2020

… Our strategy has evolved to parallel the change in technology.” About Scientia Ventures Scientia Ventures invests in early to mid-stage technology companies that target computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences. Our strength is working with entrepreneurs and big ideas to build companies with the potential to transform healthcare. Our …

Orexo eyes opioid use disorder app launch before year-end | 10/2/2020

Phil Taylor October 2, 2020 Sweden’s Orexo says its opioid use disorder (OUD) digital therapeutic – now christened Modia – is on course for a launch before the end of the year in the US. Like its earlier digital therapies for alcohol misuse and depression , Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 …

Invitation - Orexo Digital Therapeutics business update October 1 - GuruFocus.com | 9/25/2020

… October 1, at 3 pm CET . During the event, Orexo will provide an update on the company’s Digital Therapeutics business, and discuss clinical data demonstrating efficacy for both deprexis® and vorvida®, Orexo’s recently launched digital therapies in the US, and ongoing activities relating to commercialisation and marketing. Orexo will also provide an update on market access strategies and its technical platform offering, followed by a Q&A session. Presenting at …

Invitation – Orexo Digital Therapeutics business update October 1 | 9/25/2020

… October 1, at 3 pm CET. During the event, Orexo will provide an update on the company’s Digital Therapeutics business, and discuss clinical data demonstrating efficacy for both deprexis® and vorvida®, Orexo’s recently launched digital therapies in the US, and ongoing activities relating to commercialisation and marketing. Orexo will also provide an update on market access strategies and its technical platform offering, followed by a Q&A session. Presenting at …

Invitation - Orexo Digital Therapeutics business update October 1 | Benzinga | 9/25/2020

… October 1, at 3 pm CET . During the event, Orexo will provide an update on the company’s Digital Therapeutics business, and discuss clinical data demonstrating efficacy for both deprexis® and vorvida®, Orexo’s recently launched digital therapies in the US, and ongoing activities relating to commercialisation and marketing. Orexo will also provide an update on market access strategies and its technical platform offering, followed by a Q&A session. Presenting at …

Invitation - Orexo Digital Therapeutics business update October 1 | 9/25/2020

… October 1,at 3 pm CET . During the event, Orexo will provide an update on the company’s Digital Therapeutics business, and discuss clinical data demonstrating efficacy for both deprexis® and vorvida®, Orexo’s recently launched digital therapies in the US, and ongoing activities relating to commercialisation and marketing. Orexo will also provide an update on market access strategies and its technical platform offering, followed by a Q&A session. Presenting at …

Orexo, GoGoMeds partner to distribute digital addiction, depression therapies in wake of COVID-19 pandemic | FierceBiotech | 9/11/2020

… reduce physical contact and potential exposure between users and healthcare professionals, as more people turn to remote technologies and telehealth to avoid the spreading coronavirus. “Social distancing has significantly raised awareness and demand for digital therapies and online pharmacies to provide much-needed solutions for mental health issues, concerning problematic drinking patterns, depression and opioid addiction,” the two companies said in a statement , adding that the threat of COVID-19 …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | 9/9/2020

Alcohol and opioid misuse, and depression on the rise because of COVID-19 prompts response to address urgent need Morristown, New Jersey, September 9, 2020 – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will also be available …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | Benzinga | 9/9/2020

MORRISTOWN, N.J. , Sept. 9, 2020 /PRNewswire/ – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will also be available in the US in Q4 2020 through the partnership. In April of this year, the FDA released an enforcement …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | Markets Insider | Business Insider | 9/9/2020

MORRISTOWN, N.J. , Sept. 9, 2020 /PRNewswire/ – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will also be available in the US in Q4 2020 through the partnership. In April of this year, the FDA released an enforcement …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | BioSpace | 9/9/2020

MORRISTOWN, N.J. , Sept. 9, 2020 /PRNewswire/ – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will also be available in the US in Q4 2020 through the partnership. In April of this year, the FDA released an enforcement …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options - GuruFocus.com | 9/9/2020

Alcohol and opioid misuse, and depression on the rise because of COVID-19 prompts response to address urgent need PR Newswire MORRISTOWN, N.J., Sept. 9, 2020 MORRISTOWN, N.J. - Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD01, a digital therapy for the treatment of opioid use disorders, will …

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | 9/9/2020

Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options Alcohol and opioid misuse, and depression on the rise because of COVID-19 prompts response to address urgent need PR Newswire MORRISTOWN, N.J., Sept. 9, 2020 MORRISTOWN, N.J. , Sept. 9, 2020 /PRNewswire/ – Orexo and …

Planning to study in Hungary? These are the best universities | 9/4/2020

industrial income, international orientation. As we reported before, a strategic cooperation agreement on the development of digital therapies was signed by Semmelweis University, the Ministry of Innovation and Technology, and Oncompass Medicine in May. Dr József Bódis, Secretary of State for Higher Education, Innovation, and Vocational Training, emphasised that medical and health science institutions are internationally recognised elements of the Hungarian higher education system. The cooperation with Semmelweis University and …

Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion | PR Newswire | 9/3/2020

… business structure will include two verticals: Biofourmis Therapeutics: Focuses on pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to treat and manage patients with unmet clinical needs. These digital therapies work independently or in conjunction with pharmacotherapies—thereby augmenting drug efficacy, reducing costs and resulting in better patient outcomes. With Biofourmis Therapeutics’ “beyond the pill” model, pharmaceutical companies prescribe the company’s digital therapeutics solution …

Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders | PR Newswire | 9/1/2020

UPPSALA, Sweden and NEW YORK Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies , and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and Orexo Innovation Challenge in substance use disorders. Motivated by personal connections to addiction and co-morbidities, the following finalists represent companies with unique solutions that address unmet needs afflicting patients and support partners in the …

Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders | Benzinga | 9/1/2020

UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ – Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies , and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and Orexo Innovation Challenge in substance use disorders. Motivated by personal connections to addiction and co-morbidities, the following finalists represent companies with unique solutions that address unmet needs afflicting patients and …

Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders | BioSpace | 9/1/2020

UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ – Orexo AB a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies , and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and Orexo Innovation Challenge in substance use disorders. Motivated by personal connections to addiction and co-morbidities, the following finalists represent companies with unique solutions that address unmet needs afflicting patients …

Ellerca Health Changes Chronic Care Landscape Putting People First with the Launch of 360Care | PRWeb | 8/25/2020

… Health. Currently, one in three Canadians has diabetes or prediabetes. Type 2 diabetes accounts for 90 to 95 percent of cases. According to the PWC Health Research Institute report, most American consumers desire new digital therapies and connected devices as treatment options, moreover, physicians are inclined towards the use of these tools as well. Additionally, the Government of Canada aims for transformative growth in the health and bioscience industry by …

This Robot Therapist Talks to Patients Via Facebook | 8/19/2020

… childhood or deep-seeded fears. Related: Why You Need to Talk About Mental Health in the Workplace and How Technology Is Changing the Way It’s Treated “CBT is such a readily translatable treatment for digital therapies , because it’s just really structured, it’s based on data, it’s time limited and it’s evidence based,” says Dr. Ali Darcy, Woebot’s founder and CEO who has a PhD in psychology. “The big realization lightbulb …

Digital Health

Apple Watch prescription sleep app from NightWare earns FDA approval | Business Insider | 11/11/2020

Digital therapeutic companies are rolling out mental health tools rapidly thanks to a friendlier stance from the FDA‚Äîthey're even using the Apple Watch to manage PTSD. And agencies like the CMS will start covering digital therapies for their enrollees, giving developers access to large, untapped user bases. publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. For a limited …

Mental Health

Apple Watch prescription sleep app from NightWare earns FDA approval | Business Insider | 11/11/2020

Digital therapeutic companies are rolling out mental health tools rapidly thanks to a friendlier stance from the FDA‚Äîthey're even using the Apple Watch to manage PTSD. And agencies like the CMS will start covering digital therapies for their enrollees, giving developers access to large, untapped user bases. publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. For a limited …

Digital Therapeutics

Orexo Interim Report Q3 2020 | BioSpace | 11/4/2020

… EBIT of SEK 72.4 m (90.9) DTx segment EBIT of SEK -62.5 m (-), including US launch of the scientifically proven digital therapies deprexis¬Æ and vorvida¬Æ Cash flow from operating activities of SEK -12.9 … good progress made in establishing our new business area in digital therapeutics. The quarter also brought some new challenges, primarily from new legal processes and impact from Covid-19. I am pleased that we have …

COVID-19

Asabys Partners leads a round of $20 million in Sidekick | 10/29/2020

… digital therapies. This round will allow the company to advance and consolidate growth in Europe and expand its operations to the U.S. Sidekick‚Äôs fundraising efforts have been supported by EIT Digital Accelerator. The company was chosen by EIT Digital as one of the top ten fastest growing high-tech companies in Europe. 0 Suzanne Mitchell Asabys achieves his particular sextet since the outbreak of the COVID-19 in Spain …

Big Pharma

New Ventures Funds Rebrands as Scientia Ventures | PR Newswire | 10/2/2020

… opportunities in healthcare and the life sciences.” “We are encouraged by the tremendous mindset shift that is going on as Big Pharma, biotech and healthcare startups all look at themselves not as biotech or healthcare … target computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences. Our strength is working with entrepreneurs and big …

Clinical Data

Invitation – Orexo Digital Therapeutics business update October 1 | 9/25/2020

clinical data demonstrating efficacy for both deprexis® and vorvida®, Orexo’s recently launched digital therapies in the US, and ongoing activities relating to commercialisation and marketing. Orexo will also provide an update on market access strategies and its technical platform offering, followed by a Q&A session. Presenting at the event will be Nikolaj Sørensen, Chief Executive Officer, alongside Dennis Urbaniak, EVP Digital Therapeutics, and Michael Sumner, Chief Medical Officer. The …

Food and Drug Administration

Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance | PR Newswire | 7/2/2020

digital therapies deprexis ® and vorvida ® , for treatment of symptoms of depression and management of problematic alcohol misuse respectively. deprexis ® is available to patients from July 1 st and vorvida ® from July 15 th . The decision to accelerate the launch is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent US Food and Drug Administration (FDA …

Addiction Treatment

Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health – Company Announcement - FT.com | Financial Times | 12/2/2019

… Health , effective today. Dennis will lead the establishment of Orexo’s global digital health business, initially through the development of two digital therapies, OXD01 (opioid use disorder) and OXD02 (alcohol use disorder), recently licensed from GAIA … innovation. The success of Orexo with Zubsolv® in the opioid addiction treatment market creates a strong and highly synergistic platform to develop and commercialize complementary digital health solutions.” For further information, please contact Orexo AB …

Behavioral Health

Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy | PR Newswire | 11/27/2019

… to enhance our capabilities in the digital space we will of course leverage our successful commercial infrastructure to make our digital therapies a success in the United States .” Dr. Mario Weiss , CEO and Founder of … safety profiles for digital therapeutics in neuroscience, immunology, oncology, or behavioral health. With more than 140 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering as well as Regulatory and Market Access, GAIA …

Digital Health Market

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

Depending on which study you believe, the wearable and digital health market could be worth anywhere from $30 billion to nearly $90 billion in the next six years. If the numbers around the size of … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Biometric Monitoring

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… the creation of Elektra Labs roughly two years ago. Now the company is launching Atlas , which aims to catalog the biometric monitoring technologies that are flooding the consumer health market. These monitoring technologies, and the … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Cognitive Behavioral Therapy

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

… burden of disease. For example, reSET-O provides patients who are taking medication for opioid-use disorder with instantly accessible cognitive behavioral therapy, which is designed to help patients change for the better the ways … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Apple Health

Apple Watch prescription sleep app from NightWare earns FDA approval | Business Insider | 11/11/2020

Digital therapeutic companies are rolling out mental health tools rapidly thanks to a friendlier stance from the FDA‚Äîthey're even using the Apple Watch to manage PTSD. And agencies like the CMS will start covering digital therapies for their enrollees, giving developers access to large, untapped user bases. publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. For a limited …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… that. The FDA has been accelerating its clearances for software-driven products like the atrial fibrillation detection algorithm on the Apple Watch and the ActiGraph activity monitors . And big pharma companies like Roche , Pfizer and … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Elektra Labs

Medtech assessor Elektra Labs is offering free evaluations of COVID-19 biosensors to doctors | TechCrunch | 6/29/2020

Medtech assessor Elektra Labs is offering free evaluations of COVID-19 biosensors to doctors Jonathan Shieber @jshieber / 19 hours As COVID-19 cases in the U.S. continue to spike and doctors and researchers try to … Digital Medicine earlier this year. No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that Backed by venture capital firms including Founder Collective, Boost VC, Lux …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… of the products that are behind all of those billions of dollars in spending. Andy Coravos, the co-founder of Elektra Labs, certainly has. Coravos, whose parents were a dentist and a nurse practitioner, has … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Novartis

Digital healthcare is all the rage in Covid-19 times. But not everyone is invited to the party | Fortune | 6/17/2020

Novartis on that pitch (per data from Pitchbook). Earlier this week, the company filed for Chapter 11 bankruptcy protection. Even prior to the onset of the pandemic, the pre-revenue health tech company struggled to raise additional funding and furloughed the majority of its employees for two weeks in November, per CNBC —highlighting the issue of integrating digital therapies within the existing hierarchy (think pharmaceutical companies, regulators, and insurers). An …

Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients | Business Insider | 11/19/2019

Novartis to commercialize a DTx for monitoring heart failure patients and acquired wearable biosensor maker Biovotion, according to MedCity News. Business Insider Intelligence Novartis and Biofourmis seek to pinpoint early signs of heart failure exacerbations and steer treatments leveraging Biovotion wearables. Previously, Biofourmis was device agnostic, incorporating a variety of wearable tech into its digital therapies — but the buy will afford Biofourmis access to a bevy of new data via …

Pear Therapeutics

Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients | Business Insider | 11/19/2019

… exacerbations and steer treatments leveraging Biovotion wearables. Previously, Biofourmis was device agnostic, incorporating a variety of wearable tech into its digital therapies — but the buy will afford Biofourmis access to a bevy of new data … month, Novartis subsidiary Sandoz broke off ties with DTx vendor Pear Therapeutics about a year after the duo released an FDA-authorized digital treatment for substance abuse, handing commercialization responsibilities to Pear. This raised questions …

Digital Therapeutics Target Mental Health, Substance Use Disorders | 11/18/2019

digital therapies are seeking regulatory approval for their products. Digital therapies could play a unique role in tackling addiction The first two FDA-approved digital therapeutics are Pear Therapeutics’ Reset mobile medical application for substance use disorders and Reset-O , which is specifically for opioid use disorder. Both tools require a prescription and provide cognitive behavioral therapy as an adjunct to outpatient treatment under the supervision of a clinician. Reset …

Akili Interactive

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… coding bootcamp and returned to the world she was raised in by taking an internship with the digital therapeutics company Akili Interactive . Coravos always thought she wanted to be in healthcare, but there was one … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | Yahoo News | 11/12/2019

… coding bootcamp and returned to the world she was raised in by taking an internship with the digital therapeutics company Akili Interactive . Coravos always thought she wanted to be in healthcare, but there was one … industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of …

Fitbit

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | TechCrunch | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … to get any smaller. As Google’s recent acquisition bid for Fitbit and the company’s reported partnership with Ascension on “Project Nightingale” to collect and digitize more patient data shows, the intersection of technology and healthcare …

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that | Yahoo News | 11/12/2019

… of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description … to get any smaller. As Google’s recent acquisition bid for Fitbit and the company’s reported partnership with Ascension on “Project Nightingale” to collect and digitize more patient data shows, the intersection of technology and healthcare …

Noom

Walmart plans to guide employees to ‘top-performing doctors’ in a bid to cut costs | Business Insider | 10/4/2019

Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

AV regulation could be delayed due to tech underperformance | Business Insider | 10/4/2019

Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

Novo Nordisk

Walmart plans to guide employees to ‘top-performing doctors’ in a bid to cut costs | Business Insider | 10/4/2019

Novo Nordisk is partnering with Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

AV regulation could be delayed due to tech underperformance | Business Insider | 10/4/2019

Novo Nordisk is partnering with Noom to implement digital therapies for weight management 81% of banking executives see working with partners as the best path to digital transformation Microsoft just announced its foldable phone — here’s why we think the Surface Duo will be its winning smartphone model …

Humana

WellDoc and Japanese pharma firm Astellas strike a $15 million deal to codevelop a digital therapeutics tool for diabetes in Asia | Business Insider | 11/25/2019

… and commercialize its BlueStar management tool for diabetes in Asia, according to MobiHealthNews. And the duo plans to architect novel digital therapies and get them into the hands of consumers worldwide. Asia-based pharma incumbents … the rest of the story at Business Insider See Also: Humana saved $3.5 billion on Medicare Advantage members in 2018 by transitioning to value-based agreements Google and Ascension assured doubters their data-sharing venture …

Orexo Interim Report Q3 2019 | PR Newswire | 10/24/2019

… and expanding reimbursement to include other products. For Zubsolv, the immediate impact is competition in the previously exclusive contracts, WellCare, Humana and United Health Group. Longer term, Zubsolv will benefit from more payers opening up … therapeutics - increasingly seen as critical to successfully treating opioid addiction. Digital Therapies – an exciting, growing market set to improve patient outcomes The use of digital therapeutics is increasing with digital poised to play a key …

Corey McCann

Opinion: Realizing the promise of prescription digital therapeutics | STAT | 10/29/2019

Realizing the promise of prescription digital therapeutics By Corey McCann October 29, 2019 Alex Hogan/STAT S martphones and tablets have transformed almost every facet of our daily lives, making it nearly impossible to imagine … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …

Prescription digital therapeutics: reimagining disease treatment- STAT | 10/29/2019

First Opinion Realizing the promise of prescription digital therapeutics By Corey McCann October 29, 2019 Alex Hogan/STAT S martphones and tablets have transformed almost every facet of our daily lives, making it nearly impossible … how to create successful FDA submissions. The regulatory pathway for digital therapies is still very much in its infancy and must be tailored for the unique nature of these treatments. The FDA has recognized the …